Samuel Michael Owens
Professor
Also affiliated: University of North Carolina at Chapel Hill (1981–1983); Pennsylvania State University (2011–2014); Mayo Clinic (2011); Children's Hospital of Philadelphia (2020); University of Arizona (1982–1986); University of Arkansas Medical Center (1986); University of Florida Health (1991); University of Florida (1991); InterveXion Therapeutics (United States) (2014–2019); University of Pennsylvania (2020)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
S. Michael Owens' research at the University of Arkansas for Medical Sciences focuses on the pharmacological effects of substances, particularly in animal models. His work has investigated the dose-response relationships of drugs such as phencyclidine and methamphetamine, utilizing monoclonal antibodies in these studies. Owens' research also extends to the use of Sprague-Dawley rats as a model organism to understand drug mechanisms and effects. With a career spanning over 130 publications and accumulating over 3,500 citations, his scholarly contributions have been recognized with a designation as a highly cited researcher. His work has been characterized by a consistent engagement with preclinical drug research, contributing to the broader understanding of substance action and potential therapeutic interventions.
Metrics
- h-index: 37
- Publications: 133
- Citations: 3,429
Positions
-
Professor 1985–presentUniversity of Arkansas for Medical Sciences Pharmacology and Toxicology ORCID
Selected Publications
-
Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine (2020)
-
The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse (2020)
-
Pharmacokinetic, Cardiovascular and Locomotor Effects of alpha‐Pyrrolidinopentiophenone (alpha‐PVP) in Male Sprague Dawley Rats after Active Vaccination (2019)
-
Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors (2019)
-
Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats (2019)
-
Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE (2019)
-
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats (2019)
-
The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse (2019)
-
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome (2019)
-
Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats (2019)
-
Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment (2018)
-
Organ Distribution and Clearance of (3,4)‐Methylenedioxypyrovalerone (MDPV) Enantiomers in Female and Male Rats after Intravenous Administration of Racemic MDPV (2018)
-
Development and Preclinical Testing of a Vaccine for 3,4‐Methylenedioxypyrovalerone (( R,S )‐MDPV) Substance Use Disorders (2018)
-
Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse (2018)
-
The Role of Norbuprenorphine in Buprenorphine‐Induced Neonatal Abstinence Syndrome: A Pilot Study (2017)
Collaboration Network
Top Collaborators
- Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
- Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats
- The pharmacokinetics of methamphetamine self-administration in male and female rats
Showing 5 of 21 shared publications
- Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
- Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
- Synthesis of Mercapto-(+)-methamphetamine Haptens and Their Use for Obtaining Improved Epitope Density on (+)-Methamphetamine Conjugate Vaccines
- The Synthesis of Haptens and Their Use for the Development of Monoclonal Antibodies for Treating Methamphetamine Abuse
- Optimization of a methamphetamine conjugate vaccine for antibody production in mice
Showing 5 of 20 shared publications
- Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats
- (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration
- Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats
- Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats
- Development of active and passive human vaccines to treat methamphetamine addiction
Showing 5 of 19 shared publications
- Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague–Dawley rats
- Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats
- (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration
- Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats
- Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats
Showing 5 of 17 shared publications
- Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
- Synthesis of Mercapto-(+)-methamphetamine Haptens and Their Use for Obtaining Improved Epitope Density on (+)-Methamphetamine Conjugate Vaccines
- Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse
- Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
- The Synthesis of Haptens and Their Use for the Development of Monoclonal Antibodies for Treating Methamphetamine Abuse
Showing 5 of 16 shared publications
- Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration
- Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response
- The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats
- Treatment with a Monoclonal Antibody against Methamphetamine and Amphetamine Reduces Maternal and Fetal Rat Brain Concentrations in Late Pregnancy
- Pharmacological effects of two anti-methamphetamine monoclonal antibodies
Showing 5 of 15 shared publications
- Development of active and passive human vaccines to treat methamphetamine addiction
- Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
- Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response
- Anti-(+)-Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction
- Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period
Showing 5 of 8 shared publications
- Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats
- Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats
- Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
- Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
- Synthesis of Mercapto-(+)-methamphetamine Haptens and Their Use for Obtaining Improved Epitope Density on (+)-Methamphetamine Conjugate Vaccines
Showing 5 of 7 shared publications
- Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague–Dawley rats
- Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody
- The pharmacokinetics of methamphetamine self-administration in male and female rats
- Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons
- Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose
Showing 5 of 7 shared publications
- The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats
- Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats
- Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats
- Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine
- Pharmacokinetic, Cardiovascular and Locomotor Effects of alpha‐Pyrrolidinopentiophenone (alpha‐PVP) in Male Sprague Dawley Rats after Active Vaccination
Showing 5 of 7 shared publications
- Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats
- Treatment with a Monoclonal Antibody against Methamphetamine and Amphetamine Reduces Maternal and Fetal Rat Brain Concentrations in Late Pregnancy
- Pharmacological effects of two anti-methamphetamine monoclonal antibodies
- Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period
- The Fate and Function of Therapeutic Antiaddiction Monoclonal Antibodies across the Reproductive Cycle of Rats
Showing 5 of 6 shared publications
- First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers
- Optimization of a methamphetamine conjugate vaccine for antibody production in mice
- Pharmacological effects of two anti-methamphetamine monoclonal antibodies
- Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors
- Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE
Showing 5 of 6 shared publications
- Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
- Synthesis of Mercapto-(+)-methamphetamine Haptens and Their Use for Obtaining Improved Epitope Density on (+)-Methamphetamine Conjugate Vaccines
- The Synthesis of Haptens and Their Use for the Development of Monoclonal Antibodies for Treating Methamphetamine Abuse
- Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response
- Simple Radiometric Method for Accurately Quantitating Epitope Densities of Hapten–Protein Conjugates with Sulfhydryl Linkages
- (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration
- Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
- Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons
- Monoclonal antibodies as long-term antagonists of phencyclidine (PCP)1
- Phencyclidine pharmacokinetics and concentration-response relationships in the pigeon
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment
Similar Researchers
Based on overlapping research topics